--- title: "Recover Investment Losses: Class Action Initiated Against Baxter International, Inc. (BAX)" description: "A class action lawsuit has been initiated against Baxter International, Inc. (BAX) for alleged securities fraud affecting shareholders between February 23, 2022, and July 30, 2025. The complaint claim" type: "news" locale: "en" url: "https://longbridge.com/en/news/262887572.md" published_at: "2025-10-27T11:44:00.000Z" --- # Recover Investment Losses: Class Action Initiated Against Baxter International, Inc. (BAX) > A class action lawsuit has been initiated against Baxter International, Inc. (BAX) for alleged securities fraud affecting shareholders between February 23, 2022, and July 30, 2025. The complaint claims that Baxter's Novum LVP product had systemic defects leading to serious patient risks, and that the company's statements regarding the product's safety and efficacy were misleading. Shareholders who suffered losses are encouraged to contact Levi & Korsinsky LLP for potential recovery options. NEW YORK, NY / ACCESS Newswire / October 27, 2025 / If you suffered a loss on your **Baxter International, Inc.** investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/baxter-international-inc-lawsuit-submission-form?prid=174065&wire=1&utm\_campaign=24 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates. **THE LAWSUIT:** A class action securities lawsuit was filed against Baxter International, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between February 23, 2022 and July 30, 2025. **CASE DETAILS:** The filed complaint alleges that defendants made false statements and/or concealed that: (a) Baxter's recently launched product, the Novum LVP, suffered systemic defects that caused widespread malfunctions, including underinfusion, overinfusion, and complete non-delivery of fluids, which exposed patients to risks of serious injury or death; (b) Baxter was notified of multiple device malfunctions, injuries, and deaths from these defects; (c) Baxter's attempts to address these defects through customer alerts were inadequate remedial measures, when design flaws persisted and continued to cause serious harm to patients; (d) as a result, there was a heightened risk that customers would be instructed to take existing Novum LVPs out of service and that Baxter would completely pause all new sales of these pumps; and (e) based on the foregoing, Baxter's statements about the safety, efficacy, product rollout, customer feedback and sales prospects of the Novum LVPs were materially false and misleading. **WHAT'S NEXT?** If you suffered a loss in Baxter International, Inc. stock during the relevant time frame - even if you still hold your shares - go to https://zlk.com/pslra-1/baxter-international-inc-lawsuit-submission-form?prid=174065&wire=1&utm\_campaign=24 to learn about your rights to seek a recovery. **There is no cost or obligation to participate.** **WHY LEVI & KORSINSKY:** Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes. **CONTACT:** Levi & Korsinsky, LLP Joseph E. Levi, Esq. Ed Korsinsky, Esq. 33 Whitehall Street, 27th Floor New York, NY 10004 jlevi@levikorsinsky.com Tel: (212) 363-7500 Fax: (212) 363-7171 https://zlk.com/ **SOURCE:** Levi & Korsinsky, LLP View the original press release on ACCESS Newswire ### Related Stocks - [BAX.US - Baxter](https://longbridge.com/en/quote/BAX.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Baxter｜8-K：2025 财年 Q4 营收 29.74 亿美元超过预期 | | [Link](https://longbridge.com/en/news/275754681.md) | | Baxter｜10-K：2025 财年营收 112 亿美元超过预期 | | [Link](https://longbridge.com/en/news/275813380.md) | | 百特国际：折扣估值和效率提升的潜力被执行和产品风险所抵消，持有评级合理 | Josh Jennings 来自 TD Cowen 对百特国际维持持有评级，目标价为 22 美元。他提到在新领导下潜在的运营改善以及与同行相比的折扣股价。然而，他也指出影响 2026 年业绩的重大不确定性，包括运输暂停和美国静脉注射解决方案 | [Link](https://longbridge.com/en/news/275503916.md) | | 宏利金融将普通股股东的股息提高了 10.2% \| 宏利金融股票新闻 | 宏利金融的董事会宣布将季度普通股股东的股息提高 10.2%，增至每股 0.485 美元。该股息将于 2026 年 3 月 19 日支付给截至 2026 年 2 月 25 日的股东。公司还将在公开市场上购买普通股，以支持其加拿大和美国的股息再 | [Link](https://longbridge.com/en/news/275666267.md) | | Biglari Capital 敦促所有 Jack In The Box 的股东在即将召开的年度会议上投票反对董事长 David Goebel | Jack in the Box Inc：BIGLARI CAPITAL 呼吁所有 Jack in the Box 股东在即将召开的年度会议上投票反对董事长 David Goebel | [Link](https://longbridge.com/en/news/275469109.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.